PhD student Eilam Yeini and Prof. Ronit Satchi-Fainaro at Tel Aviv University. Photo courtesy of TAUGlioblastoma is a particularly aggressive form of brain cancer, accounting for half of all primary brain cancers. It has a 40 percent survival rate after a year and just 5% after five years, even after surgery, radiation and chemotherapy.
Researchers at Tel Aviv University have discovered a potential treatment, tested on mice and 3D lab models so far.
If it works on humans, glioblastoma could become “chronic but manageable”
If it works on humans, glioblastoma could become “chronic but manageable,” says Prof. Ronit Satchi-Fainaro, director of the university’s Cancer Biology Research Center and Cancer Research and Nanomedicine Laboratory. “It could even cure it completely.”
What Satchi-Fainaro and her team discovered is that glioblastoma results in part from a failure in the brain’s immune system, which leads to the amplification of cancerous cell division.
This immune system misstep is tied to the secretion of a protein called P-Selectin (SELP) which, when bound to the brain’s microglia immune cells, alters their function so that, rather than inhibiting the spread of cancer cells, they do the opposite.-- More...
Activating the brain's immune system against the deadly cancer Glioblastoma prevents from spreading
ISRAEL21c was founded in 2001, in the wake of the Second Intifada, to broaden public understanding of Israel beyond typical portrayals in the mainstream media.
The organization’s founders – Israeli-American technology executives – understood the great power of the Internet and developed a first-of-its kind online product with global appeal and reach.
